Chemours (CC) Tops Q1 EPS by 56c; Offers FY22 EBITDA Guidance

Chemours (NYSE: CC) reported Q1 EPS of $1.46, $0.56 better than the analyst estimate of $0.90. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.56 billion.

FY 2022 Adjusted EBITDA is now expected to be between $1.475 billion and $1.575 billion vs. prior guidance of between $1.3 billion and $1.425 billion. Free Cash Flow is expected to be greater than $550 million vs. prior guidance of greater than $500 million.

For earnings history and earnings-related data on Chemours (CC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
• Nike names former Pfizer CFO David Denton as new finance chief